Abstract
The 11th St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers. Any positive level of estrogen receptor (ER) expression is considered sufficient to justify the use of endocrine adjuvant therapy in almost all patients. Overexpression or amplification of HER2 by standard criteria is an indication for anti-HER2 therapy for all but the very lowest risk invasive tumours. The corollary is that ER and HER2 must be reliably and accurately measured. Indications for cytotoxic adjuvant therapy were refined, acknowledging the role of risk factors with the caveat that risk per se is not a target. Proliferation markers, including those identified in multigene array analyses, were recognised as important in this regard. The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1319-1329 |
| Number of pages | 11 |
| Journal | Annals of Oncology |
| Volume | 20 |
| Issue number | 8 |
| DOIs | |
| State | Published - 2009 |
Fingerprint
Keywords
- Early breast cancer
- St Gallen Consensus
- Therapies
ASJC Scopus subject areas
- Oncology
- Hematology
- Medicine(all)
Cite this
Thresholds for therapies : Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. / Goldhirsch, Aron; Ingle, J. N.; Gelber, R. D.; Coates, A. S.; Thürlimann, B.; Senn, H. J.
In: Annals of Oncology, Vol. 20, No. 8, 2009, p. 1319-1329.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Thresholds for therapies
T2 - Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009
AU - Goldhirsch, Aron
AU - Ingle, J. N.
AU - Gelber, R. D.
AU - Coates, A. S.
AU - Thürlimann, B.
AU - Senn, H. J.
PY - 2009
Y1 - 2009
N2 - The 11th St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers. Any positive level of estrogen receptor (ER) expression is considered sufficient to justify the use of endocrine adjuvant therapy in almost all patients. Overexpression or amplification of HER2 by standard criteria is an indication for anti-HER2 therapy for all but the very lowest risk invasive tumours. The corollary is that ER and HER2 must be reliably and accurately measured. Indications for cytotoxic adjuvant therapy were refined, acknowledging the role of risk factors with the caveat that risk per se is not a target. Proliferation markers, including those identified in multigene array analyses, were recognised as important in this regard. The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm.
AB - The 11th St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers. Any positive level of estrogen receptor (ER) expression is considered sufficient to justify the use of endocrine adjuvant therapy in almost all patients. Overexpression or amplification of HER2 by standard criteria is an indication for anti-HER2 therapy for all but the very lowest risk invasive tumours. The corollary is that ER and HER2 must be reliably and accurately measured. Indications for cytotoxic adjuvant therapy were refined, acknowledging the role of risk factors with the caveat that risk per se is not a target. Proliferation markers, including those identified in multigene array analyses, were recognised as important in this regard. The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm.
KW - Early breast cancer
KW - St Gallen Consensus
KW - Therapies
UR - http://www.scopus.com/inward/record.url?scp=69449090120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69449090120&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdp322
DO - 10.1093/annonc/mdp322
M3 - Article
C2 - 19535820
AN - SCOPUS:69449090120
VL - 20
SP - 1319
EP - 1329
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 8
ER -